Outpatient Surgery Magazine - Subscribers

Melt Your Job Stress Away - January 2014 - Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/236454

Contents of this Issue


Page 14 of 142

Page 15 For the Management of Postsurgical Pain EXPAREL® (bupivacaine liposome injectable suspension) Patient-Focused Pain Control That Lasts For Up To 72 Hours The only single-dose local analgesic to Reduce or eliminate opioids with pain control for up to 3 days Without the need for catheters or pumps Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures. The clinical benefit of the attendant decrease in opioid consumption was not demonstrated. EXPAREL is a liposome formulation of bupivacaine indicated for administration into the surgical site to produce postsurgical analgesia. Important Safety Information: EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Reference: Gorfine SR, et al. Dis Colon Rectum. Dec 2011;54(12):1552-1559. Please see brief summary of Prescribing Information on reverse side. For more information, visit www.EXPAREL.com ©2013 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054 EXP-AP-0039-201302

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Subscribers - Melt Your Job Stress Away - January 2014 - Outpatient Surgery Magazine